Delcath Systems Inc
DCTH
Market Cap$496.14M
Close$
$-3.80
125.6% downside
Current Fair Value
125.6% downsideOvervalued by 125.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $496.14 Million |
|---|---|
| Enterprise Value | $464.77 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.93 |
| Beta | 0.72 |
| Outstanding Shares | 32,014,364 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.01 |
|---|---|
| PEG | 16.49 |
| Price to Sales | - |
| Price to Book Ratio | 7.42 |
| Enterprise Value to Revenue | 22.13 |
| Enterprise Value to EBIT | -17.37 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...